

EQA round: FC1/23 - Calprotectin in Stool

Deadline: 3.3.2023

Setup: groups - measurement principle

AV = assigned value

N_{tot} = total number of the resultsN_{eva} = number of the results assessed

CVP = consensus of all participants

N_{rel} = relative number of the resultsN_{suc} = number of successful results

>>> ... expected result

S_{rel} = relative success

> ... acceptable result

± ... result not assessed

| Test Sample Group | Frequency of the results | | | | Success | | |
|------------------------------------|--------------------------|------------------|-------------------------|----------------------------------|------------------|------------------|-------------------------|
| | AV | N _{tot} | N _{rel} [%] | Result | N _{eva} | N _{suc} | S _{rel} [%] |
| (223) Calprotectin | | 72 | | | | | |
| Sample A | | 72 | | | 72 | 65 | 90 |
| (2) EIA (ELISA) | CVP >>> | 16 | 22 | Negative | | | |
| (3) FIA (FEIA, TRACE) | CVP >>> | 6 | 8,3 | Negative | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI) | CVP >>> | 16 | 22 | Negative | | | |
| (6) IMT, IMN | CVP >>> | 16 | 22 | Negative | | | |
| | | 1 | 1,4 | Inconclusive result (borderline) | | | |
| | | 1 | 1,4 | Positive | | | |
| (7) HPLC, GC | CVP >>> | 14 | 19 | Negative | | | |
| (99) Another measurement principle | CVP >>> | 2 | 2,8 | Negative | | | |
| Sample B | | 72 | | | 72 | 67 | 93 |
| (2) EIA (ELISA) | CVP >>> | 16 | 22 | Positive | | | |
| (3) FIA (FEIA, TRACE) | CVP >>> | 6 | 8,3 | Positive | | | |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI) | > | 3 | 4,2 | Inconclusive result (borderline) | | | |
| | CVP >>> | 13 | 18 | Positive | | | |
| (6) IMT, IMN | | 2 | 2,8 | Negative | | | |
| | > | 3 | 4,2 | Inconclusive result (borderline) | | | |
| | CVP >>> | 13 | 18 | Positive | | | |
| (7) HPLC, GC | | 3 | 4,2 | Negative | | | |
| | > | 2 | 2,8 | Inconclusive result (borderline) | | | |
| | CVP >>> | 9 | 13 | Positive | | | |
| (99) Another measurement principle | CVP >>> | 2 | 2,8 | Positive | | | |